Somatic Uniparental Disomy of PTEN in Endothelial Cells Causes Vascular Malformations in Patients with PTEN Hamartoma Tumor Syndrome
Authors:
- Sandra D. CastilloSCSandra D. Castillo
- Xabier PerosanzXPXabier Perosanz
- Andrew K. ResslerARAndrew K. Ressler
- Marta IvarsMIMarta Ivars
- Jairo RodríguezJRJairo Rodríguez
- Carlota RoviraCRCarlota Rovira
- Emanuele M. NolaENEmanuele M. Nola
- Judith LlenaJLJudith Llena
- Joaquim Grego-BessaJGJoaquim Grego-Bessa
- Mónica RoldánMRMónica Roldán
- Raquel ArnauRARaquel Arnau
- Anabel Martínez-RomeroAMAnabel Martínez-Romero
- 28 March 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (7) , 1350-1362
Abstract
PTEN hamartoma tumor syndrome (PHTS) is a rare tumor risk disorder caused by germline loss-of-function mutations in PTEN. Half of these patients develop vascular malformations, a hamartoma characterized by overgrowth of vessels. In this study, we harness biopsies and patient-derived endothelial cells (EC) to study the genetic etiology of PHTS-related vascular malformations. We discover that these lesions are generated by somatic loss of the PTEN wild-type allele through copy-neutral loss of heterozygosity, leading to somatic uniparental disomy of the PTEN-mutated allele in ECs. We established a mouse model of PHTS-related vascular malformations and identified that the mTOR inhibitor rapamycin and AKT inhibitor capivasertib block vascular lesion growth. As proof-of-concept for clinical activity, off-label treatment with rapamycin of two patients with PHTS reduced vascular overgrowth and abrogated lesion-associated pain. Overall, our results uncover the genetic cause of vascular malformations in patients with PHTS and open new avenues for therapeutic intervention. Significance: Somatic loss of PTEN in ECs causes vascular malformations in patients with the tumor risk syndrome PHTS. These lesions respond to PI3K signaling inhibition. See related commentary by Del Prior and Toker, p. 1306Keywords
All Related Versions
Funding Information
- Agencia Estatal de Investigación (PI20/00102)
- Ministerio de Ciencia e Innovación (PID2020-116184RB-I00 /AEI/10.13038/501100011033)
- Ministerio de Ciencia e Innovación (RYC-2022-035574-I)
- PTEN Research (IJC-21-001)
- Institut de Recerca contra la Leucèmia Josep Carreras
- Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona (LCF/BQ/PR20/11770002)
This publication has 50 references indexed in Scilit:
- Sirolimus for vascular anomalies associated with PTEN hamartoma tumor syndromePediatric Blood & Cancer, 2024
- The yield and effectiveness of breast cancer surveillance in women with PTEN Hamartoma Tumor SyndromeCancer, 2022
- Impact of vascular anomalies on the PTEN phenotype in children and young adultsPediatric Blood & Cancer, 2020
- Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1The American Journal of Human Genetics, 2019
- Somatic Activating PIK3CA Mutations Cause Venous MalformationThe American Journal of Human Genetics, 2015
- Somatic Uniparental Isodisomy Explains Multifocality of Glomuvenous MalformationsThe American Journal of Human Genetics, 2013
- Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutationPediatric Blood & Cancer, 2011
- Efficient, inducible Cre‐recombinase activation in vascular endotheliumGenesis, 2008
- Cre/loxP‐mediated inactivation of the murine Pten tumor suppressor geneGenesis, 2002
- Somatic mutations of thePTEN tumor suppressor gene in sporadic follicular thyroid tumorsGenes, Chromosomes and Cancer, 1998